This approach is expected to stabilize or slow down disease progression, but several therapeutic strategies aiming for the molecular causes of FSHD (chromatin opening, DUX4 gene expression) are in development [57,58,59,60]. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.